TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11521797

Group type: EXPERIMENTAL
Intervention: 5-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for five days during weeks one and four of radiotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 7-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for seven days during weeks one and four of radiotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall treatment (chemoradiotherapy)
Number of subjects: 31
Study: 9846284

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 13

Group type: COMPARATOR
Intervention: Flomoxef
Number of subjects: 13
Study: 8279372

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 17
Study: 2662291

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (0.1 mg/puff, 2 puffs t.d.s. for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study: 30730774

Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Collaborative and Proactive Solutions (CPS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Family permissiveness
Number of subjects: 134
Study: 29790780

Group type: EXPERIMENTAL
Intervention: One-quarter per day activation protocol
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Two-quarters per day activation protocol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (20 subjects, 11 females and 9 males, mean age 10.27 ± 1.24 years)
Number of subjects: 101
Study: 27681767

Group type: EXPERIMENTAL
Intervention: Maximum dose of radiation therapy (RT)
Number of subjects: 33
Study: 24520780

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) intervention (Jianpi Shugan Recipe)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 204
Study: 23140056

Group type: EXPERIMENTAL
Intervention: Balance Acupuncture
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 74
Study: 20153280

Group type: EXPERIMENTAL
Intervention: Controlled running training based on interval training and speed exercises
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no retraining)
Number of subjects: 85
Study: 18576337

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 16023067

Group type: EXPERIMENTAL
Intervention: Vitrectomy group (Gr I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (Gr II)
Number of subjects: 56
Study: 11926601

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group interventions
Number of subjects: 0
Study: 11117863

Group type: COMPARATOR
Intervention: Conventional radiation therapy (50 Gy in 25 fractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional radiation plus brachytherapy boost (minimum peripheral tumor dose of 60 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (Conventional radiation therapy and Conventional radiation plus brachytherapy boost)
Number of subjects: 0
Study: 8818259

Group type: EXPERIMENTAL
Intervention: One-stage procedure (removal at one visit)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Two-stage procedure (removal in two stages, 3-4 weeks apart)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 1428296

Group type: EXPERIMENTAL
Intervention: L-alpha-glycerylphosphorylcholine (alpha-GPC) 1,000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citicoline (CTC) 1,000 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no drug administration)
Number of subjects: 12
Study: 6429319

Group type: EXPERIMENTAL
Intervention: 100 mg oral metoprolol (beta-blockade)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6
Study: 29236547

Group type: EXPERIMENTAL
Intervention: Favorable story (snus framed as a safer alternative)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Mixed story (described potential risks and harm-reduction benefits)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Cautious story (described snus risks)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group (no article)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Favorable story
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Mixed story
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Cautious story
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1008
Study: 30296453

Group type: EXPERIMENTAL
Intervention: Resistance training group (RTG, 12 weeks, 3 times a week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active control group (CG, stretching classes, 12 weeks, once a week)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resistance training group (RTG)
Number of subjects: 44
Study: 27004617

Group type: EXPERIMENTAL
Intervention: 2 portions of fruit and vegetable (FV) daily for 12 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 4 portions of fruit and vegetable (FV) daily for 12 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 7 portions of fruit and vegetable (FV) daily for 12 weeks
Number of subjects: 62
Study: 25236363

Group type: EXPERIMENTAL
Intervention: FibNVT/VF1
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: FibNVT/VF2
Number of subjects: 568
Study: 21704995

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) with a locked volar plate
Number of subjects: 75

Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 75
Study: 20445490

Group type: EXPERIMENTAL
Intervention: Gel-lubricated non-hydrophilic catheter
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated catheter
Number of subjects: 25

Group type: COMPARATOR
Intervention: PVC catheter
Number of subjects: 25
Study: 17328985

Group type: EXPERIMENTAL
Intervention: Peg-IFNalpha monotherapy (180 microg weekly)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Peg-IFNalpha and ribavirin (up to maximum tolerated dose for 48 weeks)
Number of subjects: 42
Study: 16245642

Group type: EXPERIMENTAL
Intervention: PGA/PLA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PGA/PLA and resorbable hydroxylapatite
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CTG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CTG and resorbable hydroxylapatite
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flap debridement alone
Number of subjects: 20
Study: 11712808

Group type: EXPERIMENTAL
Intervention: Intravesical BCG
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Monitoring BCG with urinary tumor markers
Number of subjects: 121
Study: 9222938

Group type: EXPERIMENTAL
Intervention: 200 mmol NaCl/day (slow sodium)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 8381164

Group type: EXPERIMENTAL
Intervention: Early thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the first cycle of etoposide and cisplatin (EP) (week 3)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Late thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the last cycle of etoposide and cisplatin (EP) (week 15)
Number of subjects: 308
Study: 3617240

Group type: EXPERIMENTAL
Intervention: Microwave coagulation followed by transurethral resection (TUR)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional TUR
Number of subjects: 35
Study: 2173394

Group type: EXPERIMENTAL
Intervention: Acivicin
Number of subjects: 56

Group type: COMPARATOR
Intervention: 4'deoxydoxorubicin (esorubicin)
Number of subjects: 56
Study: 4898563

Group type: EXPERIMENTAL
Intervention: Hexoestrol, 45 mg, single injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stilboestrol, customary oral course
Number of subjects: 0
Study: 31141275

Group type: EXPERIMENTAL
Intervention: Body lotion with 3HFWC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Body lotion vehiculum (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand cream with 3HFWC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial hand cream (control)
Number of subjects: 0
Study: 31333262

Group type: EXPERIMENTAL
Intervention: Knowledge of future access to recorded lectures
Number of subjects: 78

Group type: COMPARATOR
Intervention: Knowledge of no future access to recorded lectures
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Reviewing recorded lectures
Number of subjects: 78
Study: 28791755

Group type: EXPERIMENTAL
Intervention: Apneic Oxygenation (AO)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 206
Study: 26508709

Group type: EXPERIMENTAL
Intervention: Ivabradine (2.5, 5, or 7.5 mg bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivabradine and Placebo
Number of subjects: 0
Study: 24113671

Group type: EXPERIMENTAL
Intervention: Lower-dose diclofenac submicron particle capsules 35 mg TID
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Lower-dose diclofenac submicron particle capsules 18 mg TID
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 21949275

Group type: EXPERIMENTAL
Intervention: Search-supported group (bibliographic assistance)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Search-supported group (hand-delivered information)
Number of subjects: 809

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 809
Study: 19321581

Group type: EXPERIMENTAL
Intervention: Rye whole‐grain/bran
Number of subjects: 17

Group type: COMPARATOR
Intervention: Refined wheat products
Number of subjects: 17
Study: 16289498

Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 1: 20% of calorie requirements taken as E028 extra liquid)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 2: 50% of calorie requirements taken as E028 extra liquid)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 3: 75% of calorie requirements taken as E028 extra liquid)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 4: 50% of calorie requirements taken as E028 extra powder)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 5: 50% of calorie requirements taken as Emsogen powder)
Number of subjects: 50
Study: 15304586

Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg before and 6 and 12 hours after each injection
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg before and 6 and 12 hours after each injection
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg daily for 1 week, plus tapering
Number of subjects: 84
Study: 11182530

Group type: EXPERIMENTAL
Intervention: Active nicotine patches (N = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo patches (N = 20)
Number of subjects: 38
Study: 9217952

Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (historic cohort managed expectantly)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Successful amnioinfusion (infused solution alleviated oligohydramnios for > 48 hours)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unsuccessful amnioinfusion (infused solution rapidly lost)
Number of subjects: 18
Study: 7983119

Group type: EXPERIMENTAL
Intervention: A‐V Impulse System foot pump activated during periods of stasis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exposure of the acetabulum by distraction of the femur with a hook
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adequate exposure of the femoral shaft by adduction, flexion and either internal or external rotation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 3110524

Group type: EXPERIMENTAL
Intervention: 5 mg RO 15-1788
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg RO 15-1788
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 mg RO 15-1788
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28782145

Group type: EXPERIMENTAL
Intervention: Camicinal 150 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Camicinal 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 27439601

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) infusion
Number of subjects: 101

Group type: COMPARATOR
Intervention: State-of-the-art therapy (control group)
Number of subjects: 101
Study: 25220033

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity (AS)
Number of subjects: 523
Study: 23632913

Group type: EXPERIMENTAL
Intervention: ISM (Internet‐based stress management program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISM+ (ISM plus online message board)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22082672

Group type: EXPERIMENTAL
Intervention: Celivarone 50 mg/d
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Celivarone 100 mg/d
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg/d
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg/d (after loading dose of 600 mg/d for 10 days)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 19408831

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg body weight s.c. twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated heparin (Heparin - 'Biochemie' 25.000 IU/5 ml)
Number of subjects: 60
Study: 16984771

Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Triple embryo transfer (TET)
Number of subjects: 45
Study: 15182982

Group type: EXPERIMENTAL
Intervention: 25% maximal isometric contraction of the neck extensors for 10 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 25% maximal isometric contraction of the neck extensors for 15 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control measurements (sitting quietly for 5, 10, and 15 min)
Number of subjects: 10
Study: 11318080

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily, titrated to 20 mg once daily and then 40 mg once daily as needed.
Number of subjects: 478

Group type: COMPARATOR
Intervention: Fluvastatin 20 mg once daily, titrated to 40 mg once daily and then 40 mg twice daily as needed.
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Simvastatin in CHD subgroup.
Number of subjects: 478

Group type: COMPARATOR
Intervention: Fluvastatin in CHD subgroup.
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Simvastatin in MRF subgroup.
Number of subjects: 478

Group type: COMPARATOR
Intervention: Fluvastatin in MRF subgroup.
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Simvastatin group.
Number of subjects: 478

Group type: COMPARATOR
Intervention: Fluvastatin group.
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 478
Study: 9159677

Group type: EXPERIMENTAL
Intervention: 3.5 mm sutureless clear corneal incision
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5.0 mm clear corneal incision with absorbable suture
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5.0 mm clear corneal incision with single radial suture (Group B1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5.0 mm clear corneal incision with X suture (Group B2)
Number of subjects: 200
Study: 8226146

Group type: EXPERIMENTAL
Intervention: Excessive margin group (field margins exceeded protocol specification)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Per protocol group (field margins within protocol specification)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Excessive margin group
Number of subjects: 832

Group type: COMPARATOR
Intervention: Per protocol group
Number of subjects: 832
Study: 3311275

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for 3 days as prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31188242

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27943311

Group type: EXPERIMENTAL
Intervention: FV-100 200 mg QD
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: FV-100 400 mg QD
Number of subjects: 350

Group type: COMPARATOR
Intervention: Valacyclovir 1000 mg TID
Number of subjects: 350
Study: 25264861

Group type: EXPERIMENTAL
Intervention: Muscle ischemic preconditioning (IPT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control sham test (ST)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Reference test (RT)
Number of subjects: 11
Study: 22554294

Group type: EXPERIMENTAL
Intervention: MHA (microparticle size) coated non-etched implants (G1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NHA (nanoparticle size) coated non-etched implants (G2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MHA coated after citric acid conditioning (G3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NHA coated after citric acid conditioning (G4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MHA mixed with whole human blood without surface treatment (G5)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NHA mixed with whole human blood without surface treatment (G6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MHA treated with citric acid and clot-blended (G7)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NHA treated with citric acid and clot-blended (G8)
Number of subjects: 40
Study: 21216835

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (MONO)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tacrolimus and mycophenolate mofetil therapy (COMBO)
Number of subjects: 150
Study: 18053320

Group type: EXPERIMENTAL
Intervention: Exenatide 5 µg BID for 30 weeks, then 5 µg BID for 4 weeks, then 10 µg BID for ≥ 3 years
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 217
Study: 17059921

Group type: EXPERIMENTAL
Intervention: Blake drains (19F)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Portex drains (28F)
Number of subjects: 199
Study: 12571543

Group type: EXPERIMENTAL
Intervention: Nurse-monitored structured care program with uptitration of enalapril to a target dose of 10 mg twice a day
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Nurse-monitored structured care program
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Nurse-monitored structured care program and Standard care
Number of subjects: 145
Study: 10638714

Group type: EXPERIMENTAL
Intervention: ImPACT program
Number of subjects: 237

Group type: COMPARATOR
Intervention: Attention-control program on goal-setting
Number of subjects: 237
Study: 8717103

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg/week
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 185
Study: 1458072

Group type: COMPARATOR
Intervention: Amphotericin in fat emulsion (2 g/l fat emulsion)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amphotericin in glucose (5% glucose)
Number of subjects: 22
Study: 6374085

Group type: EXPERIMENTAL
Intervention: Dicyclomine hydrochloride
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31175560

Group type: EXPERIMENTAL
Intervention: Bilateral subcostal transversus abdominis plane block (TAP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Trocar site infiltration
Number of subjects: 45
Study: 29656913

Group type: EXPERIMENTAL
Intervention: Intervention churches (n=59)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Control churches (delayed intervention)
Number of subjects: 1308
Study: 25804277

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Typical formula
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Other formulas
Number of subjects: 20
Study: 24520548

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 70
Study: 21135626

Group type: EXPERIMENTAL
Intervention: Parents exposed to media messages
Number of subjects: 404

Group type: COMPARATOR
Intervention: Children of unexposed parents
Number of subjects: 404
Study: 19729114

Group type: EXPERIMENTAL
Intervention: Systematic strategy (group B) - patients who systematically underwent pre-operative coronary angiography
Number of subjects: 208

Group type: COMPARATOR
Intervention: Selective strategy (group A) - coronary angiography performed based on noninvasive tests
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Systematic strategy (group B)
Number of subjects: 208
Study: 17679727

Group type: EXPERIMENTAL
Intervention: PLD + bortezomib
Number of subjects: 646

Group type: COMPARATOR
Intervention: bortezomib
Number of subjects: 646
Study: 15123861

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (5 mg/kg/day for 3 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 75
Study: 11374495

Group type: EXPERIMENTAL
Intervention: Exercise stress test
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dobutamine stress test
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combined exercise and dobutamine testing
Number of subjects: 42
Study: 9566630

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) based on propofol and alfentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Balanced anesthesia (BA) based on nitrous oxide, isoflurane and fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: BA
Number of subjects: 30
Study: 9471197

Group type: EXPERIMENTAL
Intervention: Thymostimulin + concurrent hyperfractionated carboplatin and irradiation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Concurrent hyperfractionated carboplatin and irradiation
Number of subjects: 36